Vasopressin antagonists in treatment of hyponatremia;Nowe metody leczenia hiponatremii - Antagoniści receptora dla wazopresyny (waptany)

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 8, 2007, Pages 356-362

  Olszewski, Waldemar ^a   Głuszek, Jerzy ^b,c  

^a Zespół Opieki Zdrowotnej ^*  (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c Uniwersytetu Medycznego Im Karola Marcinkowskiego W Poznaniu   (Poland)

Author keywords

Hyponatremia; Vaptans; Vasopressin; Vasopressin antagonists

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; ARGIPRESSIN; CONIVAPTAN; DIURETIC AGENT; LIXIVAPTAN; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; SATAVAPTAN; SODIUM CHLORIDE; TOLVAPTAN; UNCLASSIFIED DRUG; VASOPRESSIN ANTAGONIST;

CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DIURESIS; DRUG EFFICACY; ELECTROLYTE DISTURBANCE; FLUID INTAKE; FOOD AND DRUG ADMINISTRATION; HOMEOSTASIS; HOSPITAL PATIENT; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; LIVER CIRRHOSIS; REGULATORY MECHANISM; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WATER RETENTION;

EID: 35748971447     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.182     Document Type: Review

References (45)

1. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000; 342: 1581-1589.
2. Krysiak R, Okopień B, Herman ZS, Hiponatremia - powazny problem kliniczny. Medycyna po Dyplomie. 2006; 15: 52-63.
3. Phuong-Chi T, Phuong-Mai T, Phuog-Thu T. Vasopressin excess and hyponatremia. Am J Kidney Dis. 2006; 47: 727-737.
4. Hawkins RC. Age and gender as risk factors for hypernatremia and hyponatremia. Clin Chim Acta. 2003; 337: 169-172.
5. Moritz ML, Ayus JC. The pathophysiology and treatment of hyponatremic encephalopathy: an update. Nephrol Dial Transplant 2003; 18: 2486-2491.
6. Riggs JE. Neurologic manifestations of electrolyte disturbances. Neurol Clin. 2002; 20: 227-239.
7. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am. 2003; 32: 459-481.
8. Pasantes-Morales H, Franco R, Ordaz B, Ochoa LD. Mechanisms counteracting swelling in brain cells during hyponatremia. Arch Med Res. 2002; 33: 237-244.
9. Casulari LA, Costa KN, Albuquerque RC et al. Differential diagnosis and treatment of hyponatremia following pituitary surgery. J Neurosurg Sci. 2004; 48: 11-18.
10. Soupart A, Decaux G. Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications. Clin Nephrol. 1996; 46: 149-169.
11. Goh KP. Management of hyponatremia. Am Fam Physician. 2004; 69: 2387-2394.
12. Yeates KE, Morton AR Vasopressin antagonists: role in the management of hyponatremia. Am J Nephrol. 2006; 26: 348-355.
13. Yeates KE, Singer M, Morton AR. Salt and water: a simple approach to hyponatremia. CMAJ. 2004; 170: 931.
14. Adrogue HJ. Consequences of inadequate management of hyponatremia. Am J Nephrol. 2005; 25: 240-249.
15. Manning M, Sawyer WH. Development of selective agonists and antagonists of vasopressin and oxytocin. Schrier RW Vasopressin. New York. Raven Press. 1985: 131-144.
16. Palm C, Pistrosch F, Herbig K, Gross P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med. 2006; 119: S87-S92.
17. Yamamura Y, Ogawa H, Chihara T, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science. 1991; 252: 572-574.
18. Saito T, Ishikawa S, Abe K, et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatemia in patients with syndome of inappriopriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab. 1997; 82: 1054-1057.
19. Serradeil-Le Gac C, Lacour C, Valette G, et al. Characterisation of SR 121463A, a highly potent and selectie, orally active vasopressin V2 antagonist. J Clin Invest. 1996; 98: 2729-2738.
20. Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Then 1998; 287: 860-867.
21. Hirano T, Yamamura Y, Nakamura S, et al. Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000; 292: 288-294.
22. Gheorghiade M, Gattis WA, O'Connor CM, et al. Vasopressin V2 receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol. 2006; 97: 1064-1067.
23. Gross P, Verbalis J, Berl T, et al. Hyponatremia management with a once-daily, oral vasopressin V2 receptor antagonist for up to one year: first report of the tolvaptan SALT 2 study. Paper presented at: American Society of Nephrology Congress, November 11, 2005; Philadelphia, PA.
24. Lee CR, Watkins ML, Patterson H. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003; 146: 9-18.
25. Gheorghiade M, Niazi I, Ouyang J, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with congestive heart failure: results from a double blind, randomized trial. Circulation. 2003; 107: 2960-2966.
26. Gheorghiade M, Konstam MA, Udelson JE, et al. Vasopressin receptor blockade with tolvaptan in chronic heart failure: differential effects in normonatremic and hyponatremic patients. J Am Coll Cardiol. 2002; 39: 171A.
27. Udelson JE, O'Brien T, Sequeira R, et al. Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo controlled, randomized study comparing the effects of tolvaptan, furosemide and their combination. J Am Coll Cardioll. 2002; 39: 156A.
28. Gheorghiade M, Gattis WA, O'Connor CM. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 2004; 291: 1963-1971.
29. Yancy CW. Climbing the mountain of acute decompensated heart failure. The EVEREST Trials. JAMA 2007; 297: 1374-1376.
30. Gerbes AL, Gulberg V, Gines P, et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized, double blind multicenter trial. Gastroenterology. 2003; 124: 933-939.
31. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a randomized, multicenter, placebo controlled trial. Hepatology. 2003; 37: 13-15.
32. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med. 2001; 138: 18-21.
33. Vaprisol (conivaptan hydrochloride injection) prescribing information. Deerfield, IL: Astellas Pharma US, Inc. February 2007.
34. Streefkerk JO, Zwieten PA, Vasopressin receptor antagonists: pharmacological tools and potential therapetic agents. Auton Autacoid Pharmacol. 2006; 26: 141-148.
35. Ghali JK, Koren MJ, Taylor JP, et al. Efficacy and safety of oral conivaptan: a V1A/ V2 antagonist, assessed in a randomized, placebo controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Edocrinol Metab. 2006; 91: 2145-2152.
36. Greenberg A, Verbalis JG. Vasopressin receptor antagonists. Kidney Int. 2006; 69: 2124-2130.
37. Fernandez-Varo G, Ros J, Cejudo-Martin P, et al. Effect of the V1/V2-AVP receptor antagonist, conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites. J Hepatol. 2003; 38: 755-761.
38. Russel SD, Selaru P, Pyne DA, et al. Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopessin ANtagonist in CHF patients undergoing Exercise) trial. Am Heart J. 2003; 145: 179-186.
39. Gross P, Reimann D, Henschkowski, et al. Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol. 2001; 12 Suppl 17: S10-S14.
40. Soupart A, Gross P, Legross JJ. Successful long-term treatment of hyponatremia in syndrome of inapprioprate antiduretic hormone secretion with Satavaptan (SR-121463B) an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol. 2006; 1: 1154-1160.
41. Lemmens-Gruber R, Kamyar M. Vasopressin antagonists. Cell Mol Life Sci. 2006; 63: 1766-1779.
42. Wang X, Gattone V, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on Polycystic Kidney Disease Development in the PCK Rat. J Am Soc Nephrol. 2005; 16: 846-851.
43. Arai Y, Fujimori A, Sudoh K, et al. Vasopressin receptor antagonists: potential indications and clinical results. Curr Opin Pharmacol. 2007; 7: 124-129.
44. Bernier V, Morello JP, Zarruk A, et al. Pharmacologie chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 2006; 17: 232-243.
45. Sanghi P, Uretsky BF, Schwarz ER. Vasopressin antagonism: a future option in heart failure. Eur Heart J. 2005; 26: 538-543.